3:I[2885,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js"],"default"]
4:I[231,["231","static/chunks/231-9e11bdfe3b664aec.js","669","static/chunks/app/asx/%5Bticker%5D/page-bf9260c50397686f.js"],""]
5:I[9275,[],""]
7:I[1343,[],""]
8:I[8173,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","391","static/chunks/391-04d41ecccdcd4247.js","185","static/chunks/app/layout-6784eb5ba9ddff8d.js"],"Image"]
9:I[4019,["231","static/chunks/231-9e11bdfe3b664aec.js","896","static/chunks/896-78f6f35c40d7ae60.js","391","static/chunks/391-04d41ecccdcd4247.js","185","static/chunks/app/layout-6784eb5ba9ddff8d.js"],"default"]
2:T607,{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does NXS do?","acceptedAnswer":{"@type":"Answer","text":"Next Science Limited develops and commercializes innovative antimicrobial solutions using its proprietary XBIOâ„¢ technology. This technology is designed to disrupt bacterial biofilms, which are a major cause of persistent infections, in areas such as surgical site infection prevention, chronic wound care, and medical device infection management."}},{"@type":"Question","name":"Is NXS a good investment?","acceptedAnswer":{"@type":"Answer","text":"As a medical technology company with a significant market cap of N/A, NXS is considered a speculative investment. It offers substantial upside potential driven by its unique and patented biofilm-disrupting technology addressing a critical healthcare need. However, it also carries risks associated with the challenges of commercializing new medical devices, intense competition, and the need for ongoing capital to fund growth."}},{"@type":"Question","name":"What drives NXS's share price?","acceptedAnswer":{"@type":"Answer","text":"NXS's share price is primarily driven by progress in regulatory approvals for its products, successful commercialization milestones (e.g., significant sales growth, new distribution agreements), positive clinical data supporting efficacy, capital raising activities (and potential dilution), and overall investor sentiment towards the speculative medical technology sector in Australia and globally."}}]}6:["ticker","NXS","d"]
0:["1VoMnPPvuLjyw3m7WYkZq",[[["",{"children":["asx",{"children":[["ticker","NXS","d"],{"children":["__PAGE__?{\"ticker\":\"NXS\"}",{}]}]}]},"$undefined","$undefined",true],["",{"children":["asx",{"children":[["ticker","NXS","d"],{"children":["__PAGE__",{},[["$L1",["$","div",null,{"className":"space-y-12","children":[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$2"}}],["$","section",null,{"className":"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]","children":[["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"Health Care"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":["Next Science Limited"," (","NXS",")"]}],["$","p",null,{"className":"mt-4 text-sm text-slate-300","children":"Next Science Limited (ASX: NXS) is an Australian medical technology company focused on the development and commercialization of patented XBIOâ„¢ technology, designed to disrupt bacterial biofilms and reduce the impact of infection. The company offers a range of products for surgical site infection prevention, chronic wound management, and medical device infection control, operating primarily in the United States and expanding globally."}],["$","div",null,{"className":"mt-6 grid gap-4 sm:grid-cols-2","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Market Cap"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"A$-1"}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Shares on Issue"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"N/A"}]]}]]}],["$","div",null,{"className":"mt-6 flex flex-wrap gap-3 text-xs text-slate-400","children":[["$","a",null,{"href":"","className":"rounded-full border border-white/10 px-3 py-1","children":"Company Website"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"AI coverage updated hourly"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"Data from ASX filings"}]]}]]}],["$","$L3",null,{"ticker":"NXS"}],["$","section",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"AI Analysis"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm text-slate-300","children":[["$","p","Next Science is currently in a critical commercialization phase, leveraging its unique XBIOâ„¢ technology to penetrate the global market for antimicrobial solutions. Recent performance has seen the company secure key regulatory approvals, such as FDA clearances for products like XPERIENCEÂ® Surgical Irrigation and EXTREMITOÂ® Wound Gel, and establish distribution agreements to expand its commercial footprint. As a relatively early-stage MedTech company with significant R&D and commercialization costs, NXS is typically focused on revenue growth and market penetration rather than immediate profitability, often reporting net losses as it scales operations.",{"children":"Next Science is currently in a critical commercialization phase, leveraging its unique XBIOâ„¢ technology to penetrate the global market for antimicrobial solutions. Recent performance has seen the company secure key regulatory approvals, such as FDA clearances for products like XPERIENCEÂ® Surgical Irrigation and EXTREMITOÂ® Wound Gel, and establish distribution agreements to expand its commercial footprint. As a relatively early-stage MedTech company with significant R&D and commercialization costs, NXS is typically focused on revenue growth and market penetration rather than immediate profitability, often reporting net losses as it scales operations."}],["$","p","The growth outlook for Next Science is largely tied to increasing adoption rates of its XBIOâ„¢-based products in hospitals and clinics, particularly in the lucrative US market, and expanding into new international territories. Upcoming catalysts include further product launches, securing additional strategic distribution partnerships, potential for new indications or product line extensions for its core technology, and demonstrating sustained revenue growth. The strategic direction is firmly aimed at establishing XBIOâ„¢ as a leading solution in the fight against biofilm-related infections and antimicrobial resistance, positioning the company for long-term sustainable growth and eventual profitability.",{"children":"The growth outlook for Next Science is largely tied to increasing adoption rates of its XBIOâ„¢-based products in hospitals and clinics, particularly in the lucrative US market, and expanding into new international territories. Upcoming catalysts include further product launches, securing additional strategic distribution partnerships, potential for new indications or product line extensions for its core technology, and demonstrating sustained revenue growth. The strategic direction is firmly aimed at establishing XBIOâ„¢ as a leading solution in the fight against biofilm-related infections and antimicrobial resistance, positioning the company for long-term sustainable growth and eventual profitability."}]]}]]}],["$","div",null,{"className":"grid gap-6 lg:grid-cols-2","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-emerald-300","children":"Bull Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Proprietary XBIOâ„¢ technology offers a genuinely differentiated solution for disrupting biofilms, addressing a critical and growing unmet medical need in infection control.",{"children":["â€¢ ","Proprietary XBIOâ„¢ technology offers a genuinely differentiated solution for disrupting biofilms, addressing a critical and growing unmet medical need in infection control."]}],["$","li","Expanding regulatory approvals and a growing network of distribution partners, particularly in the large US market, are driving increasing product adoption and revenue growth.",{"children":["â€¢ ","Expanding regulatory approvals and a growing network of distribution partners, particularly in the large US market, are driving increasing product adoption and revenue growth."]}],["$","li","Potential for platform technology to be applied to new indications or medical devices, broadening the addressable market and creating additional revenue streams.",{"children":["â€¢ ","Potential for platform technology to be applied to new indications or medical devices, broadening the addressable market and creating additional revenue streams."]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-red-300","children":"Bear Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Significant capital requirements for ongoing R&D, manufacturing scale-up, and commercialization efforts may necessitate further dilutive capital raises.",{"children":["â€¢ ","Significant capital requirements for ongoing R&D, manufacturing scale-up, and commercialization efforts may necessitate further dilutive capital raises."]}],["$","li","Intense competition from well-established medical device companies with larger sales forces and entrenched market positions could hinder market penetration and adoption rates.",{"children":["â€¢ ","Intense competition from well-established medical device companies with larger sales forces and entrenched market positions could hinder market penetration and adoption rates."]}],["$","li","Slow uptake of new medical technologies in healthcare systems, coupled with reimbursement challenges, could delay revenue ramp-up and path to profitability.",{"children":["â€¢ ","Slow uptake of new medical technologies in healthcare systems, coupled with reimbursement challenges, could delay revenue ramp-up and path to profitability."]}]]}]]}]]}]]}],null,["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Recent Announcements"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","0",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Update - Return of Capital - NXS"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"1 Feb 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Capital Structure"}]]}],""]}],["$","div","1",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Capital Return - Change of Payment Date"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"30 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Capital Structure"}]]}],""]}],["$","div","2",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Return of Capital - NXS"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"28 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Capital Structure"}]]}],""]}],["$","div","3",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"General Meeting - Voting Results"}],false]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"27 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"General"}]]}],""]}],["$","div","4",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","div",null,{"className":"flex flex-wrap items-center gap-2","children":[["$","p",null,{"className":"font-semibold text-white","children":"Quarterly Activity Report & Appendix 4C - 31 December"}],["$","span",null,{"className":"inline-flex items-center gap-1 rounded-full border border-red-500/30 bg-red-500/10 px-2 py-0.5 text-[10px] font-semibold uppercase tracking-wider text-red-400","title":"Price sensitive","children":"ðŸš¨ Price Sensitive"}]]}],["$","div",null,{"className":"mt-1 flex flex-wrap items-center gap-3 text-xs text-slate-500","children":[["$","span",null,{"children":"27 Jan 2026"}],["$","span",null,{"className":"rounded-full border border-white/10 bg-ink-800 px-2 py-0.5","children":"Quarterly Report"}]]}],["$","p",null,{"className":"mt-2 text-xs text-slate-400","children":"NXS, a commitments test entity on ASX, reports quarterly activities and provides detailed financial data in the appendix for investors to review."}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"FAQs"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","What does NXS do?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What does NXS do?"}],["$","p",null,{"className":"text-slate-400","children":"Next Science Limited develops and commercializes innovative antimicrobial solutions using its proprietary XBIOâ„¢ technology. This technology is designed to disrupt bacterial biofilms, which are a major cause of persistent infections, in areas such as surgical site infection prevention, chronic wound care, and medical device infection management."}]]}],["$","div","Is NXS a good investment?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"Is NXS a good investment?"}],["$","p",null,{"className":"text-slate-400","children":"As a medical technology company with a significant market cap of N/A, NXS is considered a speculative investment. It offers substantial upside potential driven by its unique and patented biofilm-disrupting technology addressing a critical healthcare need. However, it also carries risks associated with the challenges of commercializing new medical devices, intense competition, and the need for ongoing capital to fund growth."}]]}],["$","div","What drives NXS's share price?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What drives NXS's share price?"}],["$","p",null,{"className":"text-slate-400","children":"NXS's share price is primarily driven by progress in regulatory approvals for its products, successful commercialization milestones (e.g., significant sales growth, new distribution agreements), positive clinical data supporting efficacy, capital raising activities (and potential dilution), and overall investor sentiment towards the speculative medical technology sector in Australia and globally."}]]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-semibold","children":"Key Metrics"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Share Price"}],["$","span",null,{"className":"font-semibold","children":["A$","0.14"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"1Y Performance"}],["$","span",null,{"className":"font-semibold text-emerald-400","children":["31.8","%"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Market Cap"}],["$","span",null,{"className":"font-semibold","children":"A$-1"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Shares on Issue"}],["$","span",null,{"className":"font-semibold","children":"N/A"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Sector"}],["$","span",null,{"className":"font-semibold","children":"Health Care"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"IPO Date"}],["$","span",null,{"className":"font-semibold","children":"18/04/2019"}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Related Stocks"}],["$","div",null,{"className":"mt-4 space-y-4","children":[["$","$L4",null,{"href":"/asx/CSL","className":"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["CSL",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"CSL Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","181.24"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-27.3","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$88.2B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L4",null,{"href":"/asx/PNV","className":"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["PNV",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Polynovo Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.99"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-13.1","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$670M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L4",null,{"href":"/asx/1AD","className":"group rounded-2xl border border-white/10 bg-ink-900/80 p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["1AD",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Adalta Limited"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.01"]}],["$","p",null,{"className":"text-xs font-semibold text-red-400","children":["-25.6","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$11M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children","$6","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},[["$","html",null,{"lang":"en","className":"__variable_6d343d __variable_49a339","children":[["$","head",null,{"children":["$","link",null,{"rel":"icon","href":"/logo.svg","type":"image/svg+xml"}]}],["$","body",null,{"className":"min-h-screen bg-ink-900 text-slate-100","children":["$","div",null,{"className":"min-h-screen","children":[["$","header",null,{"className":"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur","children":[["$","div",null,{"className":"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8","children":[["$","$L4",null,{"href":"/","className":"flex items-center gap-3","children":[["$","$L8",null,{"src":"/logo.svg","alt":"ASX Desk","width":140,"height":40,"className":"h-10 w-auto","priority":true}],["$","span",null,{"className":"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline","children":"Research Terminal"}]]}],["$","nav",null,{"className":"hidden items-center gap-6 text-sm text-slate-300 md:flex","children":[["$","$L4","/",{"href":"/","className":"transition hover:text-white","children":"Home"}],["$","$L4","/screener",{"href":"/screener","className":"transition hover:text-white","children":"Screener"}],["$","$L4","/sectors",{"href":"/sectors","className":"transition hover:text-white","children":"Sectors"}],["$","$L4","/news",{"href":"/news","className":"transition hover:text-white","children":"News"}],["$","$L4","/ipos",{"href":"/ipos","className":"transition hover:text-white","children":"IPOs"}],["$","$L4","/compare",{"href":"/compare","className":"transition hover:text-white","children":"Compare"}],["$","$L4","/about",{"href":"/about","className":"transition hover:text-white","children":"About"}]]}],["$","div",null,{"className":"hidden items-center gap-3 md:flex","children":[["$","$L9",null,{}],["$","button",null,{"className":"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20","children":"Premium Research"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400","children":"Open Account"}]]}]]}],["$","div",null,{"className":"flex items-center justify-between gap-3 border-t border-white/5 px-4 py-3 md:hidden","children":[["$","div",null,{"className":"flex-1","children":["$","$L9",null,{}]}],["$","$L4",null,{"href":"/screener","className":"shrink-0 text-xs text-blue-300","children":"Screener"}]]}]]}],["$","main",null,{"className":"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8","children":["$","$L5",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L7",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":["$","div",null,{"className":"flex min-h-[60vh] flex-col items-center justify-center text-center","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"404"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":"Page not found"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"We couldn't locate that ASX page. Try searching a ticker or visit the homepage."}],["$","$L4",null,{"href":"/","className":"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white","children":"Back to Home"}]]}],"notFoundStyles":[],"styles":null}]}],["$","footer",null,{"className":"border-t border-white/10 bg-ink-800/60","children":[["$","div",null,{"className":"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8","children":[["$","div",null,{"children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"ASX Desk"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools."}],["$","div",null,{"className":"mt-4 flex gap-3","children":[["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}],["$","button",null,{"className":"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300","children":"Download Media Kit"}]]}]]}],["$","div",null,{"className":"grid grid-cols-2 gap-6 text-sm text-slate-400","children":[["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Platform"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L4",null,{"href":"/screener","className":"hover:text-white","children":"Screener"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/news","className":"hover:text-white","children":"News & Commentary"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/about","className":"hover:text-white","children":"About"}]}]]}]]}],["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Sectors"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/materials","className":"hover:text-white","children":"Materials"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/financials","className":"hover:text-white","children":"Financials"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/health care","className":"hover:text-white","children":"Health Care"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/information technology","className":"hover:text-white","children":"Information Tech"}]}],["$","li",null,{"children":["$","$L4",null,{"href":"/sectors/energy","className":"hover:text-white","children":"Energy"}]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h4",null,{"className":"font-semibold","children":"Weekly Alpha Briefing"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox."}],["$","div",null,{"className":"mt-4 flex flex-col gap-3 sm:flex-row","children":[["$","input",null,{"type":"email","placeholder":"you@example.com","className":"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Subscribe"}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"By subscribing you agree to receive marketing updates. Unsubscribe anytime."}]]}]]}],["$","div",null,{"className":"border-t border-white/10 py-6 text-center text-xs text-slate-500","children":["$","p",null,{"children":"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results."}]}]]}]]}]}]]}],null],null],[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/5bd3404007bffd2a.css","precedence":"next","crossOrigin":"$undefined"}]],[null,"$La"]]]]]
a:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"NXS share price, analysis & company profile - Next Science Limited | ASX Desk"}],["$","meta","3",{"name":"description","content":"Latest NXS share price overview, what Next Science Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","link","4",{"rel":"canonical","href":"https://asxdesk.com/asx/NXS/"}],["$","meta","5",{"property":"og:title","content":"NXS share price, analysis & company profile - Next Science Limited"}],["$","meta","6",{"property":"og:description","content":"Latest NXS share price overview, what Next Science Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","7",{"property":"og:url","content":"https://asxdesk.com/asx/NXS/"}],["$","meta","8",{"property":"og:type","content":"article"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"NXS share price, analysis & company profile - Next Science Limited"}],["$","meta","11",{"name":"twitter:description","content":"Latest NXS share price overview, what Next Science Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","12",{"name":"next-size-adjust"}]]
1:null
